Eli Lilly said its oral weight-loss drug Foundayo reduced sleep-related breathing interruptions in adults with moderate-to-severe obstructive sleep apnea and obesity or overweight, meeting the main goal of a late-stage study. The company plans to seek U.S. approval for the treatment by year-end.
The drug reduced breathing interruptions by about 44% among patients who were not using positive airway pressure (PAP) therapy and by nearly 28% among those who were, Lilly said. After 52 weeks, roughly 32% of patients not using PAP and nearly 20% of those using it had reached remission or mild disease. The company’s account reported the first figure as “32%%.”
Lilly said Foundayo’s overall safety and tolerability profile was generally consistent with earlier trials. The most common adverse events were mild-to-moderate gastrointestinal effects.
Thomas Seck, senior vice president of product development for Lilly Cardiometabolic Health, said obstructive sleep apnea is a common complication of obesity and is closely linked to cardiovascular disease. He said the study also showed improvements in several cardiovascular risk factors. Lilly shares rose 3.1% to $1,396.02 in morning trading.
Comments (0)
No comments yet. Be the first!